Recruiting · registry status

Long-term follow-up after gene therapy

Researchers follow people who received IPS101A gene therapy for severe Parkinson’s to assess long-term safety and whether any effects last.

Learning by observing or collecting information · Study reference: NCT07629115

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported actual date): 2026-05-29
Main measurements finished (planned): 2031-07-30
Study finished (planned): 2031-10-30

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded

2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Ages 50 years to 80 years · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria * Subjects who were enrolled in the IPS101A-10 clinical trial and received IPS101A. * Subjects and/or their legally acceptable representatives who voluntarily provided written informed consent to participate in this long-term follow-up study after being fully informed of the study, and who agreed to comply with all study-related requirements. Exclusion Criteria * Subjects who decline to provide consent for participation in the long-term follow-up study, or for whom follow-up assessments are not feasible due to death or other reasons. * Subjects who, in the judgment of the investigator, are considered unsuitable for participation in the study due to unwillingness or inability to comply with scheduled study visits or other study-related requirements.

Full study name & original research details

Official study title

A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product in the IPS101A-10 Phase I Clinical Trial

Short title used by the registry

A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.

Original description

The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.

Conditions reported: Parkinson Disease; Parkinson's Disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

ClinicalTrials.gov · NCT07629115 ↗ — RECRUITING; checked 2026-10-11
ClinicalTrials.gov · NCT07629115 ↗ — Recruiting; WHO ICTRP processed 2026-07-13; checked 2026-10-11

Study type: Observational
Interventions: Not reported
Phases: Not reported
Sponsor: Innopeutics Corporation
Start date reported by registry: 2026-05-29 (actual)

Registry updated: 2026-07-01 · Status last verified by the registry submitter: 2026-06

Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

ChoLong Park · +82-2-3499-4266 · clpark@innopeutics.com

Tae-gyun Kim · contact@innopeutics.com

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Severance Hospital

Seoul, South Korea

Recruiting

Professor, MD, PhD · phlee@yuhs.ac

Facility not reported

South Korea

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.